WAYNE, Pa.--(BUSINESS WIRE)--Encorium Group, Inc. (Nasdaq: ENCO) (“Encorium”), a leader in the design and management of complex clinical trials and patient disease registries for the pharmaceutical, biotechnology and medical device industries, filed a registration statement with the Securities and Exchange Commission (SEC) on December 22, 2006 covering the shares it issued on November 1, 2006 to the former shareholders of Remedium as part of the business combination.
